Note 13. Technology Development and Licensing Agreements (Detail) (USD $)	6 Months Ended
	Jun. 30, 2012	Dec. 31, 2011
Other Accrued Liabilities, Current	$ 1,890,412	$ 2,031,934
Proceeds from License Fees Received	2,500,000
Effect on Future Cash Flows, Amount	4,000,000
Reduction in Future Drug Approval Milestone Payment With Yakult, Percentage	20.00%
Hisun [Member]
Other Accrued Liabilities, Current	20,000
Upon Closing of Preferred Equity Financing [Member]
Effect on Future Cash Flows, Amount	2,000,000
Upon Resumption of Enrollment of Japanese Patients in the Japan Cohort of the HEAT Study [Member]
Effect on Future Cash Flows, Amount	$ 2,000,000